|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2011-3-9
|
|
pubmed:abstractText |
The most accepted standard duration of neoadjuvant chemotherapy (na-CHT) before debulking surgery for advanced ovarian cancer (AOC) is 3 courses. However a percentage of patients could benefit from additional courses. [(18)F]FDG-PET/CT monitoring during na-CHT could predict early pathological response and allow the delivery of an optimal na-CHT duration.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1824-4785
|
|
pubmed:author |
pubmed-author:BernardiAA,
pubmed-author:CastellucciPP,
pubmed-author:D'Errico GrigioniAA,
pubmed-author:De IacoPP,
pubmed-author:FantlPP,
pubmed-author:LopciEE,
pubmed-author:MartoniA AAA,
pubmed-author:MustoAA,
pubmed-author:QuerciaSS,
pubmed-author:Ricci MaccariniLL,
pubmed-author:RosatiMM,
pubmed-author:ZamagniCC
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
55
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
81-90
|
|
pubmed:meshHeading |
pubmed-meshheading:21068714-Adult,
pubmed-meshheading:21068714-Aged,
pubmed-meshheading:21068714-Carboplatin,
pubmed-meshheading:21068714-Chemotherapy, Adjuvant,
pubmed-meshheading:21068714-Female,
pubmed-meshheading:21068714-Fluorine Radioisotopes,
pubmed-meshheading:21068714-Fluorodeoxyglucose F18,
pubmed-meshheading:21068714-Humans,
pubmed-meshheading:21068714-Middle Aged,
pubmed-meshheading:21068714-Neoadjuvant Therapy,
pubmed-meshheading:21068714-Neoplasm Staging,
pubmed-meshheading:21068714-Ovarian Neoplasms,
pubmed-meshheading:21068714-Paclitaxel,
pubmed-meshheading:21068714-Positron-Emission Tomography,
pubmed-meshheading:21068714-Predictive Value of Tests,
pubmed-meshheading:21068714-Radiopharmaceuticals,
pubmed-meshheading:21068714-Tomography, X-Ray Computed
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
[18F]FDG-PET/CT monitoring early identifies advanced ovarian cancer patients who will benefit from prolonged neo-adjuvant chemotherapy.
|
|
pubmed:affiliation |
Unit of Medical Oncology, S.Orsola-Malpighi University Hospital, Bologna, Italy. andrea.martoni@aosp.bo.it
|
|
pubmed:publicationType |
Journal Article
|
